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A multi-national working group on antibiotic stewardship, from the International Society of
Chemotherapy, put together ten recommendations to physicians prescribing antibiotics to
outpatients. These recommendations are: (1) use antibiotics only when needed; teach the
patient how to manage symptoms of non-bacterial infections; (2) select the adequate ATB;
precise targeting is better than shotgun therapy; (3) consider pharmacokinetics and phar-
macodynamicswhen selecting anATB; use the shortest ATB course that has proven clinical
efﬁcacy; (4) encourage patients’ compliance; (5) use antibiotic combinations only in speciﬁc
situations; (6) avoid low quality and sub-standard drugs; prevent prescription changes at
the drugstore; (7) discourage self-prescription; (8) follow only evidence-based guidelines;
beware those sponsored by drug companies; (9) rely (rationally) upon the clinical microbi-
ology lab; and (10) prescribe ATB empirically – but intelligently; know local susceptibility
trends, and also surveillance limitations.
Keywords: antibiotic stewardship, antibiotic resistance, guidelines, generic antibiotics, self-prescription, treatment
compliance
INTRODUCTION
Appropriate use of antimicrobials is deﬁned by the WHO as
“the cost–effective use of antimicrobials which maximizes clini-
cal therapeutic effect while minimizing both drug-related toxicity
and the development of antimicrobial resistance” (WHO Depart-
ment of CommunicableDisease Surveillance andResponse, 2001).
Antimicrobial resistance is one of the most urgent health threats
people are facing all around the world.
The Antimicrobial StewardshipWorking Group of the Interna-
tional Society of Chemotherapy was established in 2009, with the
aim of promoting a judicious use of antimicrobials by fostering
collaboration on a global scale. Nowadays, the ﬁve continents are
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represented in our group, and experts from all of them have par-
ticipated in the creation and discussion of these 10 tips and top
action items for the practicing physician in an outpatient setting.
These recommendations aim to guide physicians who prescribe
antibiotics (ATB) to do so with caution, in order to maintain the
usefulness of these pivotal therapeutic tools.
The members of the working group understand that there
are many other factors that strongly cause the misuse of ATB,
such as their use in agroindustry and veterinary practice (at least
half of the worldwide production), the deﬁcient medical educa-
tion regarding antimicrobial stewardship, the poor or non-existent
control of ATB production,marketing, and promotion, the lack of
community-oriented information on ATB use, and a weak regu-
lation of drugstores that triggers self-prescription, among others.
However, we are convinced that if the following simple action
items are widely known and applied, it would greatly contribute to
improve antimicrobial usage. The present document summarizes
our recommendations to improve the use of ATB in outpatient
settings.
USE ANTIBIOTICS ONLY WHEN NEEDED; TEACH THE
PATIENT HOW TO MANAGE SYMPTOMS OF
NON-BACTERIAL INFECTIONS
Studies worldwide show that at least half of prescribedATB are not
necessary or otherwise abused (Gonzales et al., 2001; Akkerman
et al., 2004; Castro et al., 2008; Dryden et al., 2009). Therefore,
despite the obvious nature of this recommendation, physicians
need to embrace this notion. For instance, ATB are often pre-
scribed against viral infections: 50–80% of patients displaying
viral symptoms receive ATB (Linder and Stafford, 2001; Castro
et al., 2008; NIHCE, 2008; Vergison et al., 2010). A particular case
is pharyngitis, where at least 80% of the cases have a viral etiol-
ogy (Cooper et al., 2001; Bisno et al., 2002), and there are clear
criteria to assess when and how to treat (Centor et al., 2007).
The very need for using ATB against streptococcal pharyngitis in
countries where rheumatic fever is not a problem, is controversial
(Del Mar et al., 2006; NIHCE, 2008). Otitis media (in children
without high fever or vomiting) (Little et al., 2001a,b; Spurling
et al., 2007) is another example where ATB are abused; the patient
(or the patient’s parents) would beneﬁt from a brief explanation
of supportive measures (anti-pyretics, baths, hydration, etc.), the
neglectable outcome difference with or without ATB, and the very
common adverse reactions, such as diarrhea or rash, that might
outweigh the beneﬁt of usingATB in upper respiratory tract infec-
tions (Linder, 2008; Coker et al., 2010). Spending a few minutes
educating our patients so that they understand the impact of
antibiotic abuse, might prevent them to seek a colleague willing
to prescribe ATB. Other situations where ATB may not be needed
include: (a) fever without other signs and symptoms of infec-
tion; (b) self-limiting bacterial infections, such as many diarrheal
diseases (Chiu et al., 1999; Sirinavin and Garner, 2000); (c) asymp-
tomatic bacteriuria, except during pregnancy (Tambyah and Maki,
2000; Nicolle et al., 2005); and (d) asymptomatic colonization of
skin ulcers, sores, andwounds. The role of ATB in themanagement
of exacerbations of chronic bronchitis (Puhan et al., 2007), fever
and minor infections in immunosuppressed patients, and atypi-
cal community-acquired pneumonia (CAP) in outpatients (Mills
et al., 2005; Shefet et al., 2005), is also controversial. A review of
ATB use and abuse has been recently published (Leekha et al.,
2011).
SELECT THE ADEQUATE ATB; PRECISE TARGETING IS
BETTER THAN SHOTGUN THERAPY
This should be another obvious recommendation, but prescrip-
tions of aminoglycosides for CAP or ceftriaxone for urinary tract
infections (UTI), for instance, are so common, that this is clearly an
issue. Physicians must know the prevalent pathogens for each kind
of infection, and the local susceptibility trends (also, ideally, the
local prevalence of resistance mechanisms). Despite the many dif-
ferent bacteria that cause infections in humans, in the outpatient
setting there is only a handful of relevant organisms: Streptococ-
cus pneumoniae, S. pyogenes, and Haemophilus inﬂuenzae causes
most bacterial respiratory infections; uropathogenic Escherichia
coli,Proteus mirabilis, and Klebsiella pneumoniae causes most UTI;
enteropathogenic E. coli, Salmonella spp., and Shigella spp. causes
most enteral infections; Staphylococcus aureus and S. pyogenes
causes skin and soft-tissue infections; Neisseria gonorrhoeae is the
most relevant sexually transmitted pathogen; H. inﬂuenzae and
N. meningitidis causes bacterial meningitis. Susceptibility trends
of these pathogens (see recommendation number 10) should be
available in a local, timely fashion, so that they can guide empirical
therapy.
Narrow spectrum drugs should be preferred when possi-
ble: wide-spectrum is only necessary when potential causative
pathogens are very diverse, or when the infection is potentially
polymicrobial. Wide-spectrum aminoglycosides are a bad choice
against pneumococcal infections (hence, not adequate for nearly
half lower respiratory tract infections), and third-generation
cephalosporins are excessive for most cases of otitis media or UTI
(in fact, plain amoxicillin is usually enough, instead of “using a
cannon to shoot a ﬂy”). Once a drug class has been selected, it is
important to avoid using those more likely to select for resistance,
such as long-half-life macrolides (Baquero, 1999), or low-potency
ﬂuoroquinolones (Credito et al., 2010).
CONSIDER PHARMACOKINETICS AND
PHARMACODYNAMICS WHEN SELECTING AN ATB; USE THE
SHORTEST ATB COURSE THAT HAS PROVEN CLINICAL
EFFICACY
Most dosage indications for ATB are decades old, when data on
PK, PD, and resistance was still emerging. In some cases, changes
have been made, such as the evolution of aminoglycoside dos-
ing, from three times per day to only once; but many deﬁciencies
are still hidden in standard treatment schemes. Physicians must
review available data on PK/PD in order to adequately select drugs
and dosing, and to prevent resistance (Li and Tang, 2005; Craig
and Slauch, 2009; Mazzei et al., 2009; Leekha et al., 2011). Drugs
belonging to the same family may signiﬁcantly differ, so that they
are not exchangeable.
Starting in the early 1980s, ATB can be classiﬁed as
concentration- or time-dependent; aminoglycosides, ﬂuoro-
quinolones, colistin and metronidazole are concentration-
dependent, while beta-lactams and most macrolides are time-
dependent (Craig, 2001). This classiﬁcation is useful in designing
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rational dosing schemes, but this information often arrived after
prescribing information was written. Also, ATB are almost always
used in adults in ﬁxed doses, unlike the common adjustments
made by pediatricians. It is unlikely that a patient of 1.50m and
45 kg would need the same dose as another of 1.90m and 110 kg;
perhaps ATB dosing must now be adjusted for weight (Falagas
and Karageorgopoulos, 2010), to avoid prescribing too little or too
much of a drug. The global increase in human weight has forced
to recalculate the average weight of passengers in airplanes and
ships, but this recalculation is still missing in drug dosing.
The length of ATB treatments was also developed when the
main concern was efﬁcacy and safety – but not resistance. Hence,
treatments were unnecessarily long. There are not enough clin-
ical trials designed to measure the efﬁcacy of shorter courses,
but well-done studies have demonstrated it for UTI (Arredondo-
García et al., 2004; Vogel et al., 2004; Kyriakidou et al., 2008;
Lutters andVogt-Ferrier, 2008), acute otitismedia (Kozyrskyj et al.,
2010), acute exacerbations of chronic bronchitis (El Moussaoui
et al., 2008; Falagas et al., 2008), acute streptococcal pharyngitis
(Altamimi et al., 2009), and acute sinusitis (Falagas et al., 2009).
In contrast, there is no supporting evidence for many of the tradi-
tional 10–14 day ATB courses, which are based more on conven-
tional wisdom or expert opinion (Mouton et al., 2011). Although
there are many factors to be considered (infection site, involved
pathogen, tissue concentration and PD of ATB, etc.) short courses
have comparable efﬁcacy with less exposure, less side effects, less
risk of resistance development and less cost. In brief: shorter is
better (Harbarth et al., 2000; D’Agata et al., 2007; Mouton et al.,
2011). Therefore,whenever available, physiciansmust rely on pub-
lished information, and shorten treatments if possible; physicians’
resistance to shorten treatmentswill only foster bacterial resistance
to ATB.
ENCOURAGE PATIENTS’ COMPLIANCE
The best ATB would fail if the patient does not comply with the
treatment. Compliance (i.e., taking the indicated doses at the indi-
cated time periods, and completing treatment as prescribed) is
in average only around 50%; there are many strategies that the
physician can use to improve patients’ compliance (Buxton, 2006).
Communication is key in this regard: physicians must ensure that
the patient understood the prescription, assist him/her in sched-
uling doses according to their activities, suggest when possible
the use of devices, from pill casings for hours or days, to the use
of PDAs or cell phones with programmable alarms. Drugs that
require only one or two doses per day usually have better com-
pliance rates; injectable ATB, on the other side, are associated to
premature discontinuation of treatments (and, with the excep-
tion of benzylpenicillin, are often completely unnecessary in the
outpatient setting). Lack of compliance can potentially lead to
resistance, due to repeated exposure to sub-inhibitory concentra-
tions of ATB, that foster the emergence of resistance (Cebrián et al.,
2006;Henderson-Begg et al., 2006; Linares et al., 2006;Cortes et al.,
2008). Patients’ understanding of this risk, as well as its health and
economic consequences to him/her, and to his/her relatives is a
responsibility that physiciansmust take themoment they prescribe
an ATB.
USE ANTIBIOTIC COMBINATIONS ONLY IN SPECIFIC
SITUATIONS
Combinations of antibiotics increase the exposure of bacte-
ria to these drugs, which select resistance, increase the costs
and have more chance of being accompanied by side effects
resulting from drug interactions. For community-acquired infec-
tions, the best drug for the job is usually a single one. Notable
exceptions include, of course, the management of tuberculosis,
where combining drugs is the best way to prevent resistance; the
therapy of moderate to severe CAP of unknown etiology, that
may includepneumococci (usually susceptible tobeta-lactams,but
growingly resistant to macrolides) or “atypical” bacteria (intrin-
sically resistant to beta-lactams, but susceptible to macrolides)
can be treated with combinations of beta-lactams and macrolides
before resorting to ﬂuoroquinolones (Miyashita et al., 2006; Man-
dell et al., 2007; Menéndez et al., 2010). Management of Heli-
cobacter pylori infections also require ATB combinations. The
emerging threat of community-acquired methicillin-resistant S.
aureus (CA-MRSA) causing skin infections, can often be faced
by adding sulfamethoxazole–trimethoprim or clindamycin, to the
beta-lactamusually prescribed for this kind of diseases (Ruhe et al.,
2007; Levy Hara et al., 2009). However, combinations lacking sup-
porting evidence, that many physicians use “just in case,” should
be avoided.
AVOID LOW QUALITY AND SUB-STANDARD DRUGS;
PREVENT PRESCRIPTION CHANGES AT THE DRUGSTORE
Terms “low quality” and “sub-standard” are used here to refer to
generic drugs that do not meet the requirements of bioequiva-
lence (98–102% of active ingredient as labeled, 85–125% of max-
imum plasma concentration, Cmax, and time-concentration area
under the curve, AUC, of the original drug). Unfortunately, even
those minimal requirements are not considered by national health
authorities of many countries. Bioequivalence is not necessarily
a test for clinical efﬁcacy (Vesga et al., 2010); furthermore, lack
of quality control, corruption, counterfeit drugs, deﬁcient control
at drugstores, etc. (Newton et al., 2010), common in developing
countries, diminish the conﬁdence on generic drugs. Additionally,
even in developed countries, generic drugs are sub-standard (Del
Tacca et al., 2009). Low quality ATB may result in pharmacokinetic
proﬁles much different from the ones of original drugs which,
in turn, may create increased periods of time of sub-inhibitory
concentration exposure, leading to treatment failure and/or resis-
tance. This is not, of course, a problem plaguing all generic drugs;
many products have shown to be bioequivalent to original ones
(Mazur et al., 1999; Galan-Herrera et al., 2009). But the “burden
of evidence” should rely on generic manufacturers, which should
demonstrate clinical efﬁcacy instead of only bioequivalence. In
many countries it is also a common practice from drugstore sales-
people to change physicians’ prescriptions. Physicians must alert
patients of this practice, which is also a risk for a complete change
of drug or modiﬁed-release formulation. (The working group that
developed these recommendations is aware that this one is contro-
versial and, in many developing countries, unaffordable; however,
we urge the reader to consider it, within the local market and
ﬁnancial features).
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DISCOURAGE SELF-PRESCRIPTION
Self-prescription, or otherwise non-medical prescription (which
includes the advice of relatives, friends or drugstore salespeople)
is not the main cause of antibiotic abuse in most countries, and
is not corrected only by requiring prescriptions to buy antibiotics.
However, the use of ATB in these uncontrolled and often unnec-
essary conditions is high in developing countries, ranging from 20
to 40% (Drug Utilization Research Group, 1997; Amábile-Cuevas
et al., 1998; Gaur and English, 2006; Grigoryan et al., 2010). From
the physician’s point of view, communicationwith patients is again
pivotal to prevent self-prescription: discussing, in lay terms, the
consequences of antibiotic abuse and its impact on their health
and economy, must go along with ATB prescription. Promoting
compliance (see recommendation number 4) also reduces a com-
mon source of self-prescription: the use of ATB leftovers, often
inadequate and expired. If communication with local pharma-
cists is possible, physicians must stress the societal risk that ATB
self-prescription poses, so that this practice is minimized.
FOLLOW ONLY EVIDENCE-BASED GUIDELINES; BEWARE
THOSE SPONSORED BY DRUG COMPANIES
Therapeutic guidelines have recently become thebasis of therapeu-
tic choices. Realizing this trend, pharmaceutical companies often
sponsor all sorts of guidelines and recommendations, pushing for
the inclusion of newer, more expensive treatment options, but
lacking experimental evidence of their superiority upon older and
cheaper drugs. Somemedical journals also join this trend by allow-
ing such biased recommendations to be published, commonly as
supplements (Rochon et al., 1994). It is crucial to look for guide-
lines based on systematic reviews of available literature, describing
levels of evidence, instead of thosemerely stating“expert opinions”
(Hippocrates once said: “There are in fact two things, science and
opinion; the former begets knowledge, the latter ignorance”). It is
unfortunately common to ﬁnd guidelines developed by specialists’
societies or groups, recommending the use of more expensive ATB
in the absence of evidence of superiority over cheaper options; the
levels of evidence to sustain such recommendations are often not
consistent with the literature.
Aside, it can also be argued that even the best treatment guide-
lines are only focused on efﬁcacy and safety, but miss the societal
side of ATB, i.e., the resistance promotion side. Furthermore, some
mathematical models predict that the use of guidelines encour-
age the intensive use of just some drugs, which rapidly select for
resistance (Laxminarayan and Weitzman, 2003). It is important
to encourage the inclusion of resistance analyses in therapeutic
guidelines, aside of efﬁcacy and safety concerns. Finally, if medi-
cine were purely a matter of guidelines, an appropriate software
may easily replace the physician; guidelines universalize individ-
ual problems, and make us face them with a very limited range of
options.
RELY (RATIONALLY) UPON THE CLINICAL MICROBIOLOGY
LAB
The microbiology laboratory can provide signiﬁcant support in
some cases of infection, although in most cases it is only used
when a ﬁrst ATB empirically prescribed has failed. By performing
cultures for the diagnosis of prevalent infections (UTI, diarrhea)
the patient can be treated in an adequate and safe way. However,
the lab cannot provide reliable answers in some cases, such as lower
respiratory tract infections, where the etiology can be assessed in
no more than half of the cases. On the other hand, the lab input
is unnecessary, as when trying to know the etiology of pharyngitis
(or the susceptibility of S. pyogenes to beta-lactams). Physicians
must be familiar with the laboratory their patients are referred to:
it should have well-documented quality controls, reference strains,
etc., so that it provide reliable results. This is particularly necessary
in countries where clinical labs run without major supervision
from health authorities. It is also crucial to know how to collect a
useful sample, and what are the limitations of each analysis (e.g.,
a nasal swab is not adequate for assessing the etiology of sinusitis;
and standard susceptibility testing cannot consider many pharma-
cokinetic and PD factors that affect clinical efﬁcacy). By choosing
a good lab, and using it only when the information it would pro-
vide is really meaningful, patients will save money and antibiotic
prescription will improve.
PRESCRIBE ATB EMPIRICALLY –BUT INTELLIGENTLY; KNOW
LOCAL SUSCEPTIBILITY TRENDS, AND ALSO SURVEILLANCE
LIMITATIONS
The need for surveillance of resistance has been highlighted many
times (German et al., 2001; WHO Department of Communica-
ble Disease Surveillance and Response, 2001; O’Brien and Stelling,
2007), but there are limited efforts to monitor resistance globally.
Developing countries often lack reliable surveillance programs,
especially of community-acquired pathogens (Tenover et al., 2001;
Chaitramet al., 2003); data in developed countries is of better qual-
ity (Bronzwaer et al., 2002), and can even be linked to usage pat-
terns.However, the amount of susceptibility data is overwhelming:
local and international meetings of infectious diseases societies are
full of posters and symposia on it. Many of these data are gener-
ated by projects sponsored by pharmaceutical companies, hence
it is important to read them carefully. Simple contradictions may
reveal bias or plain wrongdoing: if two ﬂuoroquinolones perform
signiﬁcantly different against E. coli isolates, or if the prevalence
of MRSA is very different from the resistance prevalence toward
amoxicillin–clavulanate, or if a set of pneumococci are highly
resistant to ﬂuoroquinolones but very sensitive to macrolides, we
must suspect the quality and/or transparency of these results. Fur-
thermore, many susceptibility surveillance projects are inherently
biased; researchers rely on isolates fromclinical labs,but physicians
only send patients to the lab when facing complications or initial
failure of empirically prescribed drugs. Resistance prevalence data
may therefore be overestimated (Lopardo et al., 2007), precluding
the use of ATB that might actually work.
FINAL CONSIDERATIONS
Tips that can be singled out: avoid ATB for bronchitis when pneu-
monia is not a concern; avoid ATB for watery diarrhea when
dysentery of typhoid fever is not a concern; delay the use of
ATB against otitis media for at least 48 h; consider nitrofuran-
toin instead of ﬂuoroquinolones against uncomplicated cystitis;
reserve respiratory ﬂuoroquinolones for unresponsive or high-
risk CAP patients; and avoid ﬁxed-dose combinations of ATB and
anti-inﬂammatory or anti-histaminic drugs.
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Preventing bacterial diseases is a much better way to avoid the
use of ATB and all of its consequences. Vaccines reduce disease
prevalence and ATB demand. Immunizations against inﬂuenza,
pneumococci, H. inﬂuenzae B, meningococci, and Salmonella
Typhi can have a pivotal role in reducing the need for ATB.
Pharmaceutical companies provide us with great drugs and
continuously invest in research and development; but the mar-
keting side is only aimed at promoting the use of their
products including, of course, ATB. Through many strate-
gies, pharmaceutical companies strongly inﬂuences prescrib-
ing behaviors, in ways not necessarily supported by the best
evidence; papers sponsored by big pharma are often biased
(Chren and Landefeld, 1994; Rochon et al., 1994; Levy Hara
et al., 2006; Anderson et al., 2009). Of course, this does not
only affects ATB prescription, but due again to the societal
nature of ATB effects, the trend, as well as the lack of ade-
quate regulation in many countries, makes it particularly dan-
gerous in terms of public health. Physicians must keep this in
mind.
ATB are limited, non-renewable resources (Carlet et al., 2011),
that we all need during our lives. “Every antibiotic expected by a
patient, every unnecessary prescription written by a doctor, every
uncompleted course of antibiotics, and every inappropriate or
unnecessary use in animals or agriculture is potentially signing
a death warrant for a future patient” (Dryden et al., 2009). We
should not wait for governments to implement measures that reg-
ulate drugpromotion andusage,and enforce ethical codes.Change
must start with us all.
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